STAT+: HHS plans funding for research into ibogaine for PTSD
Lilly has agreed to buy $50 million in Oura stock if certain conditions are met, though the drugmaker says those conditions haven’t been met yet, STAT’s Elaine Chen writes.
Key points
- Continue to STAT+ to read the full story….
- Want to stay on top of the science and politics driving biotech today?
- If you have any interesting tips on the matter, email me!
Oura deal may complicate Lilly’s GLP-1 telehealth ties Eli Lilly already sends patients looking for a GLP-1 prescription to Counsel Health through its pharmacy platform LillyDirect.
Now, smart ring maker Oura is buying Counsel, which could give Lilly a financial interest in a telehealth company it promotes.
Additional details
- Sign up to get our biotech newsletter in your inbox.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.